Once viewed as a potential blockbuster destined to face off against Pfizer Inc.’s Prevnar 13, Genocea Biosciences Inc.’s pneumococcus vaccine, GEN-004, fizzled in top-line data from a phase IIa trial, performing better than placebo but not well enough to hit statistical significance.